Literature DB >> 22820288

Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.

Shu-Hao Hsu1, Bo Wang, Janaiah Kota, Jianhua Yu, Stefan Costinean, Huban Kutay, Lianbo Yu, Shoumei Bai, Krista La Perle, Raghu R Chivukula, Hsiaoyin Mao, Min Wei, K Reed Clark, Jerry R Mendell, Michael A Caligiuri, Samson T Jacob, Joshua T Mendell, Kalpana Ghoshal.   

Abstract

miR-122, an abundant liver-specific microRNA (miRNA), regulates cholesterol metabolism and promotes hepatitis C virus (HCV) replication. Reduced miR-122 expression in hepatocellular carcinoma (HCC) correlates with metastasis and poor prognosis. Nevertheless, the consequences of sustained loss of function of miR-122 in vivo have not been determined. Here, we demonstrate that deletion of mouse Mir122 resulted in hepatosteatosis, hepatitis, and the development of tumors resembling HCC. These pathologic manifestations were associated with hyperactivity of oncogenic pathways and hepatic infiltration of inflammatory cells that produce pro-tumorigenic cytokines, including IL-6 and TNF. Moreover, delivery of miR-122 to a MYC-driven mouse model of HCC strongly inhibited tumorigenesis, further supporting the tumor suppressor activity of this miRNA. These findings reveal critical functions for miR-122 in the maintenance of liver homeostasis and have important therapeutic implications, including the potential utility of miR-122 delivery for selected patients with HCC and the need for careful monitoring of patients receiving miR-122 inhibition therapy for HCV.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820288      PMCID: PMC3408748          DOI: 10.1172/JCI63539

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  DNA excision in liver by an albumin-Cre transgene occurs progressively with age.

Authors:  C Postic; M A Magnuson
Journal:  Genesis       Date:  2000-02       Impact factor: 2.487

Review 2.  Enzymes of triacylglycerol synthesis and their regulation.

Authors:  Rosalind A Coleman; Douglas P Lee
Journal:  Prog Lipid Res       Date:  2004-03       Impact factor: 16.195

3.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

4.  Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.

Authors:  Catherine L Jopling; Minkyung Yi; Alissa M Lancaster; Stanley M Lemon; Peter Sarnow
Journal:  Science       Date:  2005-09-02       Impact factor: 47.728

5.  Flow cytometric identification of murine neutrophils and monocytes.

Authors:  E Lagasse; I L Weissman
Journal:  J Immunol Methods       Date:  1996-10-16       Impact factor: 2.303

6.  Identification of tissue-specific microRNAs from mouse.

Authors:  Mariana Lagos-Quintana; Reinhard Rauhut; Abdullah Yalcin; Jutta Meyer; Winfried Lendeckel; Thomas Tuschl
Journal:  Curr Biol       Date:  2002-04-30       Impact factor: 10.834

7.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.

Authors:  Catherine M Shachaf; Andrew M Kopelman; Constadina Arvanitis; Asa Karlsson; Shelly Beer; Stefanie Mandl; Michael H Bachmann; Alexander D Borowsky; Boris Ruebner; Robert D Cardiff; Qiwei Yang; J Michael Bishop; Christopher H Contag; Dean W Felsher
Journal:  Nature       Date:  2004-10-10       Impact factor: 49.962

8.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

9.  Lipid metabolism. I. Effects of pressure and gas composition on acetate-C14 incorporation into liver lipids.

Authors:  G M Adams; S J Norton
Journal:  Aerosp Med       Date:  1971-02

10.  Developmental context determines latency of MYC-induced tumorigenesis.

Authors:  Shelly Beer; Anders Zetterberg; Rebecca A Ihrie; Ryan A McTaggart; Qiwei Yang; Nicole Bradon; Constadina Arvanitis; Laura D Attardi; Sandy Feng; Boris Ruebner; Robert D Cardiff; Dean W Felsher
Journal:  PLoS Biol       Date:  2004-09-28       Impact factor: 8.029

View more
  344 in total

Review 1.  Diversifying microRNA sequence and function.

Authors:  Stefan L Ameres; Phillip D Zamore
Journal:  Nat Rev Mol Cell Biol       Date:  2013-06-26       Impact factor: 94.444

Review 2.  Micro RNAs in the development of non-alcoholic fatty liver disease.

Authors:  Glenn S Gerhard; Johanna K DiStefano
Journal:  World J Hepatol       Date:  2015-02-27

Review 3.  Genetic and epigenetic mechanisms of NASH.

Authors:  Mohammed Eslam; Jacob George
Journal:  Hepatol Int       Date:  2015-12-18       Impact factor: 6.047

4.  Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3.

Authors:  Ketti G Oliveira; Fernanda M Malta; Ana C S S Nastri; Azzo Widman; Paola L Faria; Rúbia A F Santana; Venâncio A F Alves; Flair J Carrilho; João R R Pinho
Journal:  Med Microbiol Immunol       Date:  2015-08-14       Impact factor: 3.402

Review 5.  Functional RNA structures throughout the Hepatitis C Virus genome.

Authors:  Rebecca L Adams; Nathan Pirakitikulr; Anna Marie Pyle
Journal:  Curr Opin Virol       Date:  2017-05-13       Impact factor: 7.090

6.  The effect of miRNA-122 in regulating fat deposition in a cell line model.

Authors:  Yu-Qiang Nie; Jie Cao; Yong-Jian Zhou; Xia Liang; Yan-Lei Du; Yu-Jui Yvonne Wan; Yu-Yuan Li
Journal:  J Cell Biochem       Date:  2014-05       Impact factor: 4.429

Review 7.  MicroRNAs in metabolic disease.

Authors:  Carlos Fernández-Hernando; Cristina M Ramírez; Leigh Goedeke; Yajaira Suárez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02       Impact factor: 8.311

8.  MicroRNA-10a controls airway smooth muscle cell proliferation via direct targeting of the PI3 kinase pathway.

Authors:  Ruoxi Hu; Wenchi Pan; Alexey V Fedulov; William Jester; Matthew R Jones; Scott T Weiss; Reynold A Panettieri; Kelan Tantisira; Quan Lu
Journal:  FASEB J       Date:  2014-02-12       Impact factor: 5.191

9.  Hepatitis C virus RNA functionally sequesters miR-122.

Authors:  Joseph M Luna; Troels K H Scheel; Tal Danino; Katharina S Shaw; Aldo Mele; John J Fak; Eiko Nishiuchi; Constantin N Takacs; Maria Teresa Catanese; Ype P de Jong; Ira M Jacobson; Charles M Rice; Robert B Darnell
Journal:  Cell       Date:  2015-03-12       Impact factor: 41.582

Review 10.  The role of miRNAs in cardiovascular disease risk factors.

Authors:  Joy N Jones Buie; Andrew J Goodwin; James A Cook; Perry V Halushka; Hongkuan Fan
Journal:  Atherosclerosis       Date:  2016-09-22       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.